Iterum Therapeutics reports fourth quarter and full year 2024 financial results
manilatimes.net — February 7, 2025, 05:01 PM UTC
Iterum Therapeutics announced its financial results for the fourth quarter and full year of 2024. The company received FDA approval for its antibiotic ORLYNVAH™ to treat uncomplicated urinary tract infections, marking a significant development in the market. In January 2025, Iterum repaid its exchangeable senior subordinated notes, extending its cash runway. The company reported a net loss of $24.8 million for 2024, an improvement from the previous year's loss of $38.4 million. Iterum's cash and equivalents stood at $24.1 million as of December 31, 2024, which is expected to fund operations into the second half of 2025. The company is also expanding its patent estate with a new allowance in Australia.